Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection
Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection
复制标题
DOI：
10.1007/s00432-014-1902-1
复制
发表时间：
2015-01
影响因子：
3.6
通讯作者：
Ci-hui Yan;Meng Lv;Hui Li;Xinmiao Song;Fan Yan;S. Cao;X. Ren
中科院分区：
文献类型：
--
作者：
Ci-hui Yan;Meng Lv;Hui Li;Xinmiao Song;Fan Yan;S. Cao;X. Ren
骨桥蛋白(OPN)是一种细胞外基质分泌的磷酸化糖蛋白，已报道在许多实体肿瘤中高表达。作为肺癌的重要组成部分，非小细胞肺癌(NSCLC)的高复发率也引起了科学家的高度重视。用免疫组织化学方法检测163例非小细胞肺癌组织中骨桥蛋白的表达，并用实时定量聚合酶链式反应比较28例匹配的骨桥蛋白在癌组织和癌旁组织中的表达。结果骨桥蛋白在肿瘤组织中的阳性表达率为66.8%，且肿瘤部位骨桥蛋白的表达明显高于癌旁组织(p=0.0046)。进一步分析发现，OPN的表达与NSCLC预后不良密切相关。而且，对于早期患者，骨桥蛋白(−)组的OS和DFS率显著高于OPN(+)组。结论OPN在非小细胞肺癌中普遍表达，对非小细胞肺癌患者，尤其是早期患者的预后有一定的指导意义。
PurposesOsteopontin (OPN), an extracellular matrix-secreted phosphorylated glycoprotein, has been reported overexpressed in many solid tumors. As an important part of lung cancer, the high recurrence of non-small cell lung cancer (NSCLC) also attracted great attention of scientists.MethodsIn this study, we investigated the expression of OPN and the relationship with prognosis of NSCLC patients. We measured the expression of OPN among 163 NSCLC samples by immunohistochemical method and compared the expression of these 28 matched cDNA between tumor and peritumoral tissue by real-time polymerase chain reaction.ResultsWe demonstrated that the percentages of positive OPN expression is 66.8 % and OPN expression in tumor site was much higher than the tissue adjacent to carcinoma (p= 0.0046). By further analysis, we found that OPN expression was significantly correlated with poor prognosis of NSCLC. Moreover, for early-stage patients, OS and DFS rates of OPN (−) group were significantly higher than OPN (+) group. For advanced-stage patients, OPN expression was only associated with OS rates.ConclusionsThese results suggest that OPN is commonly expressed in NSCLC and may guide the evaluation of prognosis with NSCLC, especially for early-stage patients.